Glaukos COO shares product updates, 2021 pipeline

January 31, 2021
David Hutton

,
Alex Delaney-Gesing

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.


See more Glaucoma 360 coverage